Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Kymera Therapeutics (KYMR) Leases (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Leases for 7 consecutive years, with $42.4 million as the latest value for Q4 2025.

  • Quarterly Leases fell 10.67% to $42.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.4 million through Dec 2025, down 10.67% year-over-year, with the annual reading at $42.4 million for FY2025, 10.67% down from the prior year.
  • Leases for Q4 2025 was $42.4 million at Kymera Therapeutics, down from $42.9 million in the prior quarter.
  • The five-year high for Leases was $56.6 million in Q1 2023, with the low at $8.9 million in Q4 2022.
  • Average Leases over 5 years is $33.3 million, with a median of $44.5 million recorded in 2025.
  • The sharpest move saw Leases soared 508.19% in 2023, then fell 12.85% in 2024.
  • Over 5 years, Leases stood at $9.4 million in 2021, then dropped by 5.48% to $8.9 million in 2022, then surged by 494.29% to $52.9 million in 2023, then dropped by 10.46% to $47.4 million in 2024, then decreased by 10.67% to $42.4 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $42.4 million, $42.9 million, and $46.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.